Search

Displaying results 2691 - 2700 of 7186 in total
  1. Drug

    Influenza B virus B/Victoria/705/2018 BVR-11 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15706
    ApprovedInvestigationalWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  2. Drug

    Influenza A virus A/Victoria/2454/2019 IVR-207 (H1N1) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB15711
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  3. Drug

    Influenza B virus B/Victoria/705/2018 BVR-11 antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB15713
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  4. Drug

    Influenza A virus A/Hong Kong/2671/2019 NIB-121 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15715
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  5. Drug

    Influenza B virus B/Washington/02/2019 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15716
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  6. Drug

    Influenza A virus A/Hawaii/66/2019 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB15756
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  7. Drug

    Influenza B virus B/Washington/02/2019 live (attenuated) antigen

    go.drugbank.com/drugs/DB15758
    Approved

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

  8. Drug

    Olsalazine

    go.drugbank.com/drugs/DB01250
    Approved

    [A257078] Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. … [A257063] It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine].

  9. Drug

    Ibandronate

    go.drugbank.com/drugs/DB00710
    ApprovedInvestigational

    Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid]. … [A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.

  10. Drug

    Vestronidase alfa

    go.drugbank.com/drugs/DB12366
    ApprovedInvestigational

    In clinical trials, vestronidase alfa treatment demonstrated improvement and stabilization in motor symptoms by increasing the patients' ability to walk longer distances in comparison to treatment with … MPS VII is a progressive condition that affects most tissues and organs due to the lack of a lysosomal enzyme called beta-glucuronidase, leading to buildup of toxic metabolites.